Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL12: Ibrutinib in Binet stage A CLL
NCT02863718Phase 3Completed
- Sponsor
- German CLL Study Group
- Start
- Apr 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Apr 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02863718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863718.